Clara Bloomfield, blood cancer expert and destroyer of glass ceilings, dies at 77

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In 1989, I joined Cancer and Leukemia Group B and was introduced into the clinical trials world and a mighty force for good, Dr. Clara D. Bloomfield.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Electra D. Paskett, PhD
Marion N. Rowley Professor of Cancer Research, director, Division of Cancer Prevention and Control, Department of Internal Medicine, professor, Division of Epidemiology, College of Public Health, associate director, population sciences and community outreach, Comprehensive Cancer Center, director, Center for Cancer Health Equity, Ohio State University
Table of Contents

YOU MAY BE INTERESTED IN

The NHS-Galleri trial presented at ASCO was the largest, prospective, randomized trial of a multicancer early detection test (MCED) to date. The study enrolled approximately 143,000 asymptomatic adults (ages 50-77) and was the first of its kind to assess clinical utility of an MCED test for cancer screening. 
Electra D. Paskett, PhD
Marion N. Rowley Professor of Cancer Research, director, Division of Cancer Prevention and Control, Department of Internal Medicine, professor, Division of Epidemiology, College of Public Health, associate director, population sciences and community outreach, Comprehensive Cancer Center, director, Center for Cancer Health Equity, Ohio State University

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login